Endometrial Biopsy in India and UAE | Complete Patient Guide

• INDICATIONS (Who Should Have This Procedure):

• Postmenopausal women with any episode of uterine bleeding (postmenopausal bleeding is endometrial carcinoma until proven otherwise)

• Premenopausal women aged ≥45 with abnormal uterine bleeding (AUB) unresponsive to first-line medical therapy

• Women of any age with AUB and endometrial thickness ≥4 mm (postmenopausal) or ≥12 mm (premenopausal, non-secretory phase) on TVUS

• Women on tamoxifen therapy (breast cancer survivors) with endometrial thickening or breakthrough bleeding

• Women using unopposed exogenous estrogen with clinical symptoms

• Chronic anovulation syndromes (PCOS, hypothalamic amenorrhea) with prolonged estrogen exposure

• Surveillance biopsy for known endometrial hyperplasia without atypia (typically at 3- and 6-month intervals following progestogen therapy)

• Infertility workup where endometrial receptivity or chronic endometritis is suspected (CD138 IHC staining for plasma cells)

• Lynch syndrome (hereditary non-polyposis colorectal cancer / HNPCC) carriers — annual endometrial surveillance from age 35

• Women with first-degree relatives diagnosed with endometrial carcinoma before age 50

• REQUIRED PRE-PROCEDURE DIAGNOSTICS:

• Transvaginal ultrasound (TVUS) — endometrial thickness measurement and myometrial assessment

• Saline infusion sonohysterography (SIS/SHG) if focal intracavitary pathology is suspected

• Complete blood count (CBC), coagulation profile (PT/aPTT/INR), and blood group

• Pregnancy test (urine or serum β-hCG) — mandatory prior to procedure

• Pap smear / cervical cytology (if not current within 3 years)

• STI/cervical infection screen (chlamydia, gonorrhea) if pelvic inflammatory disease is a differential

• CA-125 and HE4 serum biomarkers if concurrent adnexal pathology or malignancy risk is elevated

• MRI pelvis with contrast — not required for biopsy itself but indicated if deep myometrial invasion or extrauterine disease is suspected prior to definitive surgical staging

• CONTRAINDICATIONS (Absolute):

• Confirmed intrauterine pregnancy

• Active pelvic inflammatory disease (PID) or acute cervicitis

• Acute hematological emergency with uncorrected coagulopathy

• Cervical carcinoma (biopsy approach changes to colposcopy-directed cervical biopsy)

• CONTRAINDICATIONS (Relative — Caution / Modification Required):

• Severe cervical stenosis (may require osmotic dilators — laminaria — the day prior, or procedural sedation)

• Anticoagulation therapy (warfarin, DOACs — discuss bridging or temporary cessation with prescribing physician)

• Significant uterine fibroids distorting the cavity (hysteroscopy preferred)

• Patient inability to tolerate speculum examination without sedation

STANDARD APPROACH — OFFICE ENDOMETRIAL BIOPSY (PIPELLE ASPIRATION): The Pipelle de Cornier sampler (Laboratoire CCD, France) is the globally validated first-line instrument. Its 3.1 mm outer diameter allows transcervical passage without cervical dilation in 85–92% of patients. The procedure takes 5–10 minutes under no anesthesia or with intracervical local anesthetic block (1–2 mL of 1% lignocaine at the 3- and 9-o'clock positions of the cervical stroma). A single-pass sampling method yields adequate tissue in approximately 91% of premenopausal and 80–85% of postmenopausal women. The Tao Brush (Cook Medical) — a rotating cytological brush with nylon bristles — is an alternative that yields higher cellularity for cytological rather than histological assessment, used when Pipelle access fails. ACCURACY: Meta-analyses demonstrate sensitivity of 81% for endometrial cancer overall, rising to 96% for Grade 2–3 lesions; specificity exceeds 98%.

HYSTEROSCOPY-DIRECTED BIOPSY (GOLD STANDARD FOR FOCAL LESIONS): When office Pipelle sampling is inadequate or when TVUS/SHG identifies a focal polyp, submucosal fibroid (FIGO Type 0–1), or localized endometrial thickening, hysteroscopy-directed biopsy under direct visualization is performed. Modern 2.9–4 mm rigid or semi-rigid hysteroscopes with 30° optics are used with normal saline as the distension medium (bipolar systems eliminate the fluid-deficit risk of monopolar glycine systems). Biopsies are taken from the most suspicious areas — fundus, tubal ostia, and any visible lesions — using 5 Fr biopsy forceps passed through the operating channel. This modality detects focal lesions missed by blind sampling in 15–20% of cases. The procedure is performed under IV sedation or general anesthesia as a day-surgery case.

OFFICE HYSTEROSCOPY (NO-TOUCH TECHNIQUE / VAGINOSCOPY): Developed by Bettocchi and Selvaggi, the no-touch vaginoscopic hysteroscopy technique eliminates the need for a speculum and tenaculum by using normal saline flow to gently dilate the vaginal walls and create a panoramic view, advancing through the cervix without grasping. This dramatically reduces procedural pain (VAS scores reduced by 30–40% versus conventional hysteroscopy) and is performed without anesthesia in an office setting. GAF Healthcare partner hospitals in both India and the UAE offer this technique, which is particularly valuable for nulliparous patients and those with cervical hypersensitivity.

SONOHYSTEROGRAPHY (SHG) COMBINED WITH BIOPSY: Saline infusion sonohysterography, performed just prior to Pipelle biopsy during the same visit, delineates the endometrial contour and identifies focal versus diffuse thickening, optimizing biopsy targeting and clinical interpretation.

EMERGING TECHNOLOGY — DIGITAL HYSTEROSCOPY AND AI-ASSISTED PATHOLOGY: Several JCI-accredited centers affiliated with GAF Healthcare now deploy 4K digital hysteroscopes with narrow-band imaging (NBI) that enhances the vascular pattern of early endometrial neoplasia, allowing real-time visual risk stratification before biopsy. AI-assisted digital pathology platforms (e.g., Paige.AI, Proscia) are being integrated into histopathology workflows at select centers, reducing inter-observer variability in endometrial hyperplasia grading. Molecular pathology panels (POLE mutation analysis, MMR-IHC, p53 IHC) conforming to the ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) algorithm are available at GAF Healthcare partner institutions, enabling ESGO/ESTRO/ESP 2023 guideline-compliant molecular subtyping from the initial biopsy sample.

FRACTIONAL CURETTAGE (D&C): Although largely superseded by hysteroscopy-directed biopsy, fractional dilatation and curettage (endocervical curettage followed by endometrial curettage) remains indicated in resource-adaptive settings or when hysteroscopy is unavailable. It provides separate endocervical and endometrial specimens, which is critical for distinguishing primary endometrial carcinoma extending to the cervix (FIGO Stage II) from primary endocervical adenocarcinoma — a distinction with significant staging and surgical implications.

PHASE 1 — PRE-TRAVEL AND REMOTE CONSULTATION (Weeks 1–2 before travel):

• GAF Healthcare case manager reviews existing TVUS reports, clinical notes, and menstrual history uploaded via secure patient portal

• Remote video consultation with the assigned consultant gynecologist / gynecologic oncologist at the partner hospital

• Pre-procedure blood panel and pregnancy test arranged at a local lab in the patient's home country; results uploaded for review

• E-Medical Visa application (India) or entry visa facilitation (UAE) initiated; typically issued within 3–5 business days

• Travel itinerary, airport pickup, and accommodation for patient and one attendant confirmed by GAF Healthcare concierge team

PHASE 2 — ARRIVAL AND SAME-DAY / NEXT-DAY BIOPSY:

• Day 1: Airport transfer to partner hospital or designated hotel; check-in and rest

• Day 2 (or Day 1 if travel permits): Hospital admission (outpatient unit); nursing assessment, vital signs, weight, and allergy documentation

• Pre-procedure: NSAIDs administered orally 30–60 minutes before procedure (e.g., ibuprofen 400–600 mg or mefenamic acid 500 mg) to reduce uterine cramping; intracervical local anesthetic block offered if needed

• Procedure (5–15 minutes): Patient positioned in dorsal lithotomy; bimanual examination to confirm uterine size/position; speculum insertion; cervical antiseptic preparation; Pipelle (or hysteroscope) introduced transcervically; tissue aspiration or hysteroscopic biopsy performed; specimen immediately labeled and dispatched to histopathology

• Post-procedure observation: 30–60 minutes in recovery area; vital signs monitored; pain assessment; ambulation confirmed before discharge

• Discharge criteria: Minimal cramping manageable with oral analgesia, no heavy bleeding, no vasovagal signs; patient discharged to hotel or hospital room (if short stay elected)

PHASE 3 — WAITING FOR PATHOLOGY (Days 2–5):

• Standard H&E histopathology report: 48–72 hours

• Extended IHC panel (ER, PR, p53, MMR proteins): Additional 24–48 hours

• Patient remains in-country during this period; GAF Healthcare arranges optional medical tourism activities, interpreter support, and dietary accommodation

• Results consultation: Consultant gynecologist reviews findings with patient via in-person clinic appointment or video call; treatment planning discussion initiated based on WHO 2023 classification and ProMisE molecular subtype

PHASE 4 — DISCHARGE AND FIT-TO-FLY ASSESSMENT:

• Fit-to-fly assessment conducted at the Day 2–3 post-procedure clinic review

• Criteria: No active bleeding beyond light spotting, no pelvic infection signs, hemodynamically stable, preliminary pathology reported

• Most patients are cleared for international air travel within 24–72 hours of the procedure

• Comprehensive discharge summary, histopathology report, IHC panel results, and recommended next-step management plan provided in both digital (PDF) and hard-copy formats

• GAF Healthcare post-departure support: Telemedicine follow-up at 1 week and 4 weeks; coordination with the patient's home-country oncologist or gynecologist for further management

PHASE 5 — POST-PROCEDURE RECOVERY AT HOME:

• Days 1–5 post-procedure: Mild uterine cramping and light spotting are expected and normal; managed with NSAIDs

• Avoid: Tampon use, sexual intercourse, and swimming pools for 5–7 days

• Return to normal daily activities: 24–48 hours post-procedure for desk/sedentary work; 48–72 hours for moderate physical activity

• Warning signs requiring urgent medical attention: Heavy bleeding (>1 pad per hour), fever >38.5°C, foul-smelling vaginal discharge, severe lower abdominal pain — contact GAF Healthcare emergency line immediately